Fedratinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Fedratinib. Educational only — not medical advice.
Labeled uses
INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Source: FDA labeling via NIH DailyMed (set f0f55a2a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.